These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 36444790)

  • 1. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
    Halim PA; Sharkawi SMZ; Labib MB
    Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiprofilerative activity against resistant cancer cells, dual β-tubulin/c-Src inhibition, cell cycle arrest and apoptosis induction.
    Abdelall EKA; A H Elshemy H; Labib MB; E A Mohamed F
    Bioorg Chem; 2022 Mar; 120():105591. PubMed ID: 34998122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis of novel chromene-based scaffolds targeting hepatocellular carcinoma: Cell cycle arrest, cytotoxic effect against resistant cancer cells, apoptosis induction, and c-Src inhibition.
    Abdelall EKA; Elshemy HAH; Labib MB; Mohamed FEA
    Drug Dev Res; 2024 Feb; 85(1):e22133. PubMed ID: 37971069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
    A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
    Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
    Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
    Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
    Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
    Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.
    Sobh EA; Kassab AE; El-Khouly EA; S A Hassan M
    Bioorg Chem; 2024 Mar; 144():107158. PubMed ID: 38301427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
    Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
    Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
    Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
    Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
    Sobh EA; Khalil NA; Faggal SI; Hassan MSA
    Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pyrrolidine-carboxamide derivatives as dual antiproliferative EGFR/CDK2 inhibitors.
    Frejat FOA; Zhao B; Furaijit N; Wang L; Abou-Zied HA; Fathy HM; Mohamed FAM; Youssif BGM; Wu C
    Chem Biol Drug Des; 2024 Jan; 103(1):e14422. PubMed ID: 38230772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation.
    Yevale DB; Teraiya N; Lalwani TD; Ameta RK; Sangani CB
    Bioorg Chem; 2023 Dec; 141():106901. PubMed ID: 37797455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
    Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
    Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity.
    Shawky AM; Almalki FA; Abdalla AN; Youssif BGM; Abdel-Fattah MM; Hersi F; El-Sherief HAM; Ibrahim NA; Gouda AM
    Eur J Med Chem; 2023 Nov; 259():115712. PubMed ID: 37567059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
    AboulWafa OM; Daabees HMG; El-Said AH
    Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction.
    Gaber AA; Abo Elmaaty A; Sharaky M; Mosa AA; Yahya Abdullah Alzahrani A; Shaaban S; Eldehna WM; Al-Karmalawy AA
    Bioorg Chem; 2024 Apr; 145():107223. PubMed ID: 38387399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
    Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
    Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
    Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
    Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.